Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,967.38
(
1.18%
)
US TECH 100
25,140.80
(
-0.01%
)
Dow Jones
48,535.99
(
0.66%
)
Brent Oil
93.78
(
-1.77%
)
Bitcoin
73,982.68
(
-0.30%
)
News Focus
News Focus
Post# of 257406
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122868
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: acgood post# 130740

Thursday, 11/10/2011 12:19:26 PM

Thursday, November 10, 2011 12:19:26 PM

Post# of 257406
The third phase-2 trial—the one that wasn’t ready for reporting in today’s PR—tests Lipitor ± REGN727 for 12 weeks with a safety follow-up at 20 weeks (http://www.clinicaltrials.gov/ct2/show/NCT01288443 ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today